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Background:  Pertussis  can  cause  severe  illness  and  death  in  infants.  Immunization  of family  members  with
the tetanus  toxoid,  reduced  diphtheria  toxoids,  and  acellular  pertussis  (Tdap)  vaccine  can  decrease  risk of
pertussis  infection  among  infants.  A community  pharmacy  on  a women’s  hospital  campus  implemented
a  Tdap  vaccination  pilot  program.
Objective:  To  investigate  the  rate of  Tdap  vaccination  among  close  contacts  of  neonates  in a women’s
hospital  pharmacy  and  to assess  the  impact  of a coordinated  pharmacy  and  hospital  Tdap  vaccination
program.
Methods:  The  intervention  entailed  education  from  hospital  staff  who  explained  the  risks  of  pertus-
sis,  advocated  the beneﬁts  of vaccination,  and  encouraged  family  members  to  be vaccinated.  In  the
on-site  clinic  or  in  the  pharmacy,  pharmacists  administered  vaccine  to  eligible  patients.  Rates  of  Tdap
vaccinations  in  the  intervention  pharmacy  with  in-hospital  vaccination  were  compared  to comparison
pharmacies  without  Tdap interventions.
Results:  In the pre-study  period  (December  2008–November  2010),  there  were  31 Tdap  vaccinations
administered  at the  intervention  pharmacy  (mean  =  1.3/month);  during  the  study  period  (December
2010–November  2012),  2045  Tdap  vaccinations  were  administered  (mean  =  85.2/month).  In four  compar-
ison  hospital-campus  pharmacies,  there were  77  vaccinations  (mean  = 0.8/month)  during  the  pre-study
period  and  817  vaccinations  (mean  = 8.5/month)  during  the  study period.  There  were  155 vaccinations
administered  in  44 area-community  pharmacies  (mean  =  0.1/month)  during  the  pre-study  period  and
2930  (mean  = 2.8/month)  during  the  study  period.  The intervention  pharmacy  had  the  highest  average
monthly  rate  of  change  in Tdap  volume  from  pre-study  to  study  period  (83.9),  compared  to  compari-
son  hospital-campus  pharmacies  (7.7, p < .001)  and  area-community  pharmacies  (2.7, p <  .001).  During
the  study  period,  the  estimated  Tdap  vaccination  coverage  per  live  births  was  8.1% in the  intervention
pharmacy  versus  5.5%  in  the  comparison  hospital-campus  pharmacies  (p <  .001).
Conclusions:  Tdap  vaccination  rates  increased  after  implementation  of  the  intervention  program.  This
project  illustrates  how  health  systems  and  community  pharmacists  can  collaborate  to improve  patient
 201
care.
©
. Introduction
Pertussis infection, caused by the pathogen Bordetella pertussis,
s a serious public health problem. In 2012, there were more than
1,000 cases of pertussis reported in the United States, with the
ajority of deaths occurring among infants younger than 3 months
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of age [1]. There has recently been a huge resurgence of the disease
– in 2012, the United States experienced the largest outbreak of
pertussis in 50 years [2]. Direct medical costs due to pertussis ill-
ness in the United States vary according to age, but are highest
in infants because a large proportion require inpatient care [3]. A
study conducted in 2000 estimated the average medical costs of
pertussis for infants aged 0–23 months to be $2822. Infants were
the most expensive group and the only group in the study to incur
hospitalization costs. In addition, parents lost an average of 6 work
days to care for a sick child due to pertussis illness [4]. Another
study in 2005 found that the average length of stay for a pertussis
Open access under CC BY-NC-ND license.hospitalization to be 6 days at a cost of $9130 per stay [5].
Adolescents and young adults are becoming infected with
pertussis as a result of waning levels of immunity from the
last dose of diphtheria toxoid-tetanus toxoid-acellular pertussis
 license.
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accine (DTaP), received at 4–6 years of age [6]. Previous stud-
es have found that vaccine effectiveness of the 5-dose DTaP
eries against pertussis infection wanes over time [7,8]. A recent
tudy suggests that the risk of acquiring pertussis increases 42%
ach year after vaccination with the 5-dose DTaP series [7], and
nother study estimates that immunity from pertussis considerably
anes 5–6 years after vaccination [8]. In response to this wan-
ng pertussis immunity, a booster vaccination containing a tetanus
oxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap)
as developed in 2005 for individuals aged 11–64 years of age
9]. However, infants who are too young to receive a full series of
mmunizations against pertussis are greatly susceptible to the com-
lications of pertussis infection. It has been estimated that 76–83%
f infant pertussis cases are contracted from adolescents and adults
ith waning immunity, including close contacts and adult family
embers [10,11]. Deaths due to pertussis infection occur primarily
n children younger than 6 months of age, and research suggests
hat the B. pertussis pathogen may  also contribute to sudden infant
eath syndrome [12,13].
The Global Pertussis Initiative of 2001 recommended imple-
entation of the “cocoon strategy” – immunizing parents,
randparents, childcare providers, healthcare personnel, and any
ther close contacts of neonates, within the prenatal period or
 weeks of birth, in order to reduce the risk of transmission to sus-
eptible newborns [14,15]. In 2006, the Advisory Committee on
mmunization Practices (ACIP) and the Centers for Disease Con-
rol and Prevention (CDC) recommended that adolescents and
dults aged <65 years (e.g., parents, siblings, grandparents, child-
are providers, and healthcare personnel) who have or anticipate
aving close contact with an infant aged <12 months should receive
 single dose of Tdap to protect against pertussis if they have
ot received Tdap previously [9]. Subsequently in 2011, the ACIP
xpanded its recommendations for adults aged 65 years and older
o receive a single dose of Tdap if they have or anticipate having
lose contact with an infant aged <12 months and previously have
ot received Tdap [16]. Despite recommendations, Tdap vaccina-
ion rates are estimated at 56% for adolescents [16] and 3.6% for
dults [17].
Cost, lack of access, and inconvenience are likely to be barriers
o vaccination among adults. Retail community pharmacies, espe-
ially those located onsite at hospitals, are uniquely positioned
o increase immunization rates in the United States for vaccine-
reventable diseases and to address this speciﬁc sub-optimal Tdap
accination rate. Pharmacists currently provide clinical services
eyond traditional dispensing roles, including providing immun-
zations [18,19], medication therapy management services [20,21],
nd disease state management [22,23]. The CDC refers to phar-
acies as non-traditional locations to receive vaccines, offering
dvantages such as community-based locations, access, and con-
enience [24]. The CDC indicates that in the 2010–2011 inﬂuenza
eason, 18.4% of people were vaccinated in a store (e.g., super-
arket or drug store) [25]. Pharmacists have become a signiﬁcant
rovider of inﬂuenza immunizations and have had great suc-
ess in pharmacist-managed immunization campaigns [26–28].
n addition to inﬂuenza, pharmacists have also become signiﬁ-
ant providers of Tdap vaccinations [29]. Pharmacists are currently
uthorized to administer Tdap vaccinations under a protocol or
ith a patient speciﬁc prescription in 43 states and the District
f Columbia [30].
On the Northwestern Memorial Hospital (NMH) campus, Pren-
ice Women’s Hospital (PWH) delivers 10,000–12,000 babies each
ear. PWH  has implemented and achieved success with a program
o vaccinate postpartum women; they reported 78.87% of postpar-
um patients received the Tdap vaccination between June 2008 and
ovember 2009 [31]. The objective of this study is to investigate
he rate of Tdap vaccination among close contacts of neonates in a2 (2014) 521– 525
women’s hospital pharmacy and to assess the impact of a coordi-
nated pharmacy and hospital Tdap vaccination program.
2. Material and methods
2.1. Program description
Walgreens operates a retail pharmacy on the Northwestern
Memorial Hospital (NMH) campus. The pharmacists at this loca-
tion are certiﬁed immunizers and maintain an ample supply of
Tdap vaccine. While the Prentice Women’s Hospital (PWH) has
achieved a high vaccination rate of postpartum patients, the num-
ber of close contacts receiving the Tdap vaccination at the retail
pharmacy has been minimal. On occasion, some fathers and close
contacts presented to the pharmacy to request the vaccine, which
was administered under a standing order protocol.
On December 9, 2010, Walgreens and PWH  implemented a pro-
gram to increase Tdap vaccination uptake among close contacts
of neonates through educating this population on the importance
of receiving the vaccine and referring them to the pharmacy for
vaccination. Prior to this initiative, there was no formal education
or referral for close contacts of neonates. Educational materials
regarding the risks of pertussis, importance of the Tdap vaccina-
tion, and promotion of the hospital vaccination clinic were added
to the existing admission packet given to delivering families. Also
included in the admission packet were a vaccine administration
record (VAR) and vaccine information sheet (VIS). These materi-
als included the time and location of pharmacist daily vaccination
clinics. For up to two hours each weekday, an on-site pharmacist
held a pertussis vaccination clinic at PWH. The entire staff of the
delivery unit was educated on the program and was responsible for
its promotion. Pharmacists and staff were available to respond to
any questions from patients.
2.2. Study design
This cross-sectional study analyzed all Tdap vaccinations
administered at the Walgreens pharmacy located on the Pren-
tice Women’s Hospital campus (intervention pharmacy with
in-hospital vaccination) between December 2008 and November
2012. The pre-study period was deﬁned as 24 months prior to ini-
tiation of the program, with Tdap vaccination claims administered
from December 2008 through November 2010. The study period
spanned 24 months after initiation of the program from December
2010 through November 2012. Four Walgreens retail pharmacies
located on hospital campuses in Illinois and Indiana were selected
as a comparison group (comparison hospital-campus pharmacies);
these pharmacies were located on hospitals with labor and delivery
services and offered Tdap vaccinations but did not have any Tdap
intervention programs. For further comparison, an additional group
of 44 Walgreens retail community pharmacies (area-community
pharmacies) which also offered Tdap vaccinations but did not have
any Tdap programs and which were in close proximity to the Pren-
tice Women’s Hospital pharmacy were analyzed.
Vaccination records during the study period were identiﬁed
from pharmacy claims extracted from the pharmacy computer
system for purposes of the study. Tdap vaccinations were deter-
mined from the Food and Drug Administration (FDA) National Drug
Code (NDC11). Since ACIP recommendations explicitly state that
the Tdap vaccination should be administered to close contacts of
neonates, vaccinations which were identiﬁed as adult formulation
of tetanus and diphtheria toxoid vaccines (Td) were excluded from
the study.
In order to establish the magnitude of the effect of the Tdap
program, descriptive statistics compared rates of Tdap vaccinations
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per month per pharmacy) in the intervention pharmacy with in-
ospital vaccination to rates in the comparison pharmacies, both
efore and after initiation of the program. In order to measure
imilarity between intervention and comparison pharmacy patient
opulations, mean age and gender were assessed using a Student’s
-test and Pearson’s chi-square test, respectively. Average monthly
ate of change in Tdap vaccination volume was calculated from the
re-study period to the study period for each of the 24 months;
.g., the ﬁrst month of the pre-study period (December 2008) was
ompared to the corresponding ﬁrst month of the study period
December 2010) and a rate of change was calculated. Wilcoxon
ank-Sum Tests were used to examine differences in the average
onthly rates of change between the intervention and comparison
harmacies.
The percent of eligible close contacts of neonates who  received
dap vaccinations was estimated by dividing the number of Tdap
accinations administered by the number of live births during the
re-study and study periods at the intervention pharmacy with
n-hospital vaccination and the four comparison hospital-campus
harmacies. Annual live birth counts were obtained from publicly
vailable registry databases from the Illinois and Indiana Depart-
ents of Public Health [32,33]. For the pre-study period, annual
irth rates from 2008 and 2009 were totaled; for the study period,
he annual rates from 2010 to 2011 were totaled. Z-tests were used
o assess the difference in rates per close contact. The exact num-
er of eligible close contacts for each live birth was not able to be
scertained from the available data.
Statistical signiﬁcance was assessed at the ∝ = 0.05 level. All data
nalysis was performed with SAS 9.2 software (SAS Institute Inc.,
ary NC). This study was approved by Quorum IRB #26510.
. Results
Mean (SD) age for intervention pharmacy with in-hospital vac-
ination patients was 38.5 years [10.4, range 14.1–88.0] versus
9.5 years [13.7, range 12.4–96.6] for comparison hospital-campus
harmacy patients (p = .06, Table 1). Compared to intervention
harmacy with in-hospital vaccination patients, mean (SD) age for
he comparison area-community pharmacy patients was  39.7 years
14.2, range 8.2–88.1] (p < .001). In an effort to assess a proxy of the
ate of close contacts, the intervention pharmacy with in-hospital
accination immunized a greater proportion of males (88.1%) than
he comparison hospital-campus pharmacies (79.8%, p < 001). The
ntervention pharmacy with in-hospital vaccination also vacci-
ated a greater proportion of males when compared to the group
f area-community pharmacies (64.5%, p < .001).
In the pre-study period, there were 31 Tdap vaccinations admin-
stered at the intervention pharmacy with in-hospital vaccination
Table 2). Mean rate of vaccination per month was  1.3, ranging from
 vaccinations per month to 8 vaccinations per month in November
010. In the study period, there were 2045 vaccinations (85.2 mean
accinations per month) administered in the intervention phar-
acy. The minimum monthly rate of Tdap vaccination was 58 in
pril 2012, while the maximum monthly rate was  163 vaccinations
n November 2012.
In the four comparison hospital-campus pharmacies with no
dap intervention, there were 77 Tdap vaccinations administered
uring the pre-study period. Mean vaccinations per month for
he four pharmacies was 0.8 (min = 0, max  = 2.5). During the study
eriod, there were 817 Tdap vaccinations administered (8.5 vacci-
ations per month per pharmacy; min  = 1.0, max  = 12.3).
In the 44 area-community pharmacies located in close proxim-
ty to the intervention pharmacy with in-hospital vaccination, there
ere 155 Tdap vaccinations (0.1 mean vaccinations per month
er pharmacy) during the pre-study period (min = 0.02, max  = 0.5). (2014) 521– 525 523
During the study period, there were 2930 vaccinations (2.8 mean
vaccinations per month per pharmacy; min  = 0.3, max = 9.4).
For the intervention pharmacy with in-hospital vaccination, the
average monthly change in volume of Tdap vaccinations was 83.9
from the pre-study period to the study period. This rate is sig-
niﬁcantly higher than the average monthly change for the four
comparison hospital-campus pharmacies with no intervention pro-
gram (7.7, p < .001) as well as the group of 44 area-community
pharmacies (2.7, p < .001).
The estimated Tdap vaccination coverage per live births was
0.1% in the intervention pharmacy with in-hospital vaccination
during the pre-study period (Table 3). During the study period,
this percent coverage increased to 8.1%. In the four compari-
son hospital-campus pharmacies with no intervention program,
the percent of Tdap vaccinations per live births was 0.5% (pre-
study period) to 5.5% (study period). During the study period, the
Tdap vaccination coverage level per live births was  46.7% greater
(p < .001) in the intervention pharmacy than the four comparison
hospital-campus pharmacies with no intervention program.
4. Discussion
The intervention pharmacy with in-hospital vaccination
demonstrated a higher rate of Tdap vaccinations among close con-
tacts of neonates than a group of four comparison hospital-campus
pharmacies with no Tdap intervention, as well as a group of 44 area-
community pharmacies with no program. This greater increase in
Tdap vaccinations illustrates the effectiveness of the intervention
program, thus compelling close contacts of neonates to receive
the Tdap vaccination. These comparison pharmacies also showed
an increase from the pre-study period to the study period. This
increase suggests that pharmacies are becoming another destina-
tion for receiving Tdap and other vaccinations.
Our study demonstrates the value of the community pharmacy
in overcoming barriers to immunization. Previous studies have
indicated that patients trust the pharmacist to administer immun-
izations and value the ease of access [34]. A recent study suggests
that retail pharmacy clinics have had an expanded role in the
delivery of vaccinations to patients; in 2009, vaccinations were
administered to patients at 1952,610 visits, up from 469,330 visits
in 2007 [35]. In 2012, the Illinois state legislature passed a mandate
requiring all entering sixth and ninth graders to receive the Tdap
vaccination prior to the school year [36]. The availability of Tdap
vaccinations at local pharmacies may  be beneﬁcial in supporting
legislature in Illinois as well as other states where mandates exist.
Results of our study suggest that the implementation of a col-
laborative program between Prentice Women’s Hospital and an
on-site Walgreens pharmacy successfully increased Tdap vacci-
nation uptake among close contacts of neonates. Previous studies
have also illustrated that education initiatives and vaccination pro-
grams conducted by healthcare personnel can successfully increase
uptake of Tdap vaccinations among close contacts of neonates. One
study reported a Tdap vaccination rate of 80.5% among all women
admitted to the obstetrics unit of the Yale-New Haven Hospital,
resulting in a 70.5% increase after implementation of a pharmacist-
driven protocol [37]. Another study conducted at Stony Brook
University Medical Center neonatal intensive care unit indicated
that after implementation of an education program by hospital
staff, Tdap vaccination rate was 86.9% among 598 parents of chil-
dren gestationally aged 23–42 weeks who were admitted to the
unit [38].Previous studies also demonstrate that interventions promoting
cocooning of close contacts of neonates have also had a posi-
tive impact in the underserved community. A study at a pediatric
ofﬁce with a hospital-based clinic demonstrated that offering Tdap
524 B. Mills et al. / Vaccine 32 (2014) 521– 525
Table 1
Demographic characteristics of patients receiving Tdap vaccinations, by intervention and comparison pharmacies.
Intervention pharmacy with
in-hospital vaccination (n = 1)
Comparison hospital-campus pharmacies (n = 4) Area-community pharmacies (n = 44)
Age*
Mean (SD) age 38.5 years [10.4, range 14.1–88.0] 39.5 years [13.7, range 12.4–96.6] 39.7 years [14.2, range 8.2–88.1]
Gender
Male  1828 (88.1%) 713 (79.8%) 2047 (64.5%)
Female 248 (11.9%) 180 (20.2%) 1129 (35.5%)
Source: Walgreens pharmacy claims data, December 2008 through November 2012.
* Calculated on date of vaccination administration.
Table 2
Pre-study and study period Tdap vaccinations in intervention and comparison pharmacies.
Pre-study period (12/2008 through 11/2010) Study period (12/2010 through 11/2012)
Total vaccines Vaccines/month Vaccines/month/pharmacy Total vaccines Vaccines/month Vaccines/month/pharmacy
Intervention pharmacy with
in-hospital vaccination
(n = 1)
31 1.3 1.3 2045 85.2 85.2
Comparison hospital-campus
pharmacies (n = 4)
77 3.2 0.8 817 34.0 8.5
Area-community pharmacies
(n = 44)
155 6.5 0.1 2930 122.1 2.8
Total  263 11.0 0.2 5792 241.3 4.9
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source: Walgreens pharmacy claims data, December 2008 through November 2012
ilcoxon Rank-Sum Test for signiﬁcant average monthly rates of change: Intervent
ilcoxon Test Statistic = 876, p < 001. Intervention pharmacy with in-hospital vacci
accinations to infant caregivers from low-income families
ncreased adult Tdap vaccination to 69%. These adults may  oth-
rwise have poor access to medical care [39]. Another study
llustrated that a cocooning initiative in a predominantly Hispanic,
edically underserved, uninsured population at a Houston hospital
uccessfully administered Tdap vaccinations to 75% of postpartum
omen [40]. These studies also suggest that Labor and Delivery staff
re essential in inﬂuencing close contacts of infants and promoting
dap vaccinations.
If no on-site pharmacy existed for close contacts of neonates,
umerous barriers to receiving the Tdap vaccine would exist, such
s seeking vaccine at a later date at another location. The collab-
rative program between Walgreens and the Prentice Women’s
ospital provides immediate access to Tdap vaccinations for close
ontacts of neonates, who are in critical need of the immunization
n order to protect their newborns from a deadly pertussis infection..1. Limitations
A major limitation of this study is the assumption that all Tdap
oses administered that were not coded as booster vaccinations
able 3
stimated Tdap vaccination coverage per live births in intervention and comparison hosp
Intervention pharmacy wit
in-hospital vaccination (n =
Pre-study period 
Tdap vaccinations administered 31 
Total  live birthsa 24,230 
%  Tdap vaccination coverage per live birthsb 0.1% 
ources: Walgreens pharmacy claims data, December 2008 through November 2012; annu
atabases from the Illinois and Indiana Departments of Public Health [32,33].
a For pre-study period (December 2008 through November 2010), annual live birth c
tudy  period (December 2010 through November 2012), annual live birth counts for 2010
b Sample calculation: intervention pharmacy with in-hospital vaccination during stud
ive  births at hospital in study period][100%] = 8.1%.
** Statistically signiﬁcant difference (Z-test statistic = 9.662, p < .001) from % Tdap vacci
tudy  period (5.5%).armacy with in-hospital vaccination vs. comparison hospital-campus pharmacies:
 vs. area-community pharmacies: Wilcoxon Test Statistic = 300, p < .001.
were administered for cocooning. It is probable that some doses
of Tdap were for tetanus prophylaxis administered for wound care
management.
Because each delivering family has a different number of eli-
gible close contacts, an exact vaccination rate in close contacts
was not able to be calculated. The mean number of Tdap vac-
cinations administered per live births was calculated in order
to estimate the coverage level among close contacts, although
this metric does not ascertain how many close contacts exist
for each live birth. In addition, follow-up was  not ascertained.
Unless a family member received their vaccination at the Pren-
tice Women’s Hospital pharmacy, we  did not attribute a program
effect to any subsequent Tdap vaccination they may have received.
While the program was promoted throughout the hospital, we
could not measure whether some staff promoted the program more
effectively than others. Even though there was no formal interven-
tion program for Tdap vaccination at the comparison pharmacies
(four comparison hospital-campus and 44 community pharma-
cies), there may  have been informal counseling of close contacts
of neonates at these locations, thus inﬂuencing Tdap vaccination
rates.
ital-campus pharmacies.
h
 1)
Comparison hospital-campus pharmacies (n = 4)
Study period Pre-study period Study period
2045 77 817
25,197 15,172 14,764
8.1%** 0.5% 5.5%
al live birth counts from 2008–2011 were obtained from publicly available registry
ounts for 2008–2009 were totaled for intervention and comparison hospitals; for
–2011 were totaled.
y period = [2045 total Tdap vaccinations administered in study period/25,197 total
nation coverage per live births in comparison hospital-campus pharmacies during
cine 32
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. Conclusions
Tdap vaccination rates increased among close contacts of
eonates after implementation of the pilot program (educational
ollaboration of pharmacy and delivery unit), thus implementing
he “cocoon strategy” as outlined by the Global Pertussis Initiative
f 2001. Increasing uptake of Tdap vaccination may  help mini-
ize health complications in neonates and their close contacts,
hus reducing direct and indirect costs caused by pertussis disease.
mplementation of the program also provided an opportunity for
ommunity pharmacists to collaborate and establish rapport with
ealth system employees and physicians. Based on this pilot, other
harmacies in the Chicagoland area have started similar Tdap vac-
ination clinics, which may  also be beneﬁcial in supporting state
andates for Tdap vaccination.
This project illustrates how health systems and community
harmacists can collaborate to improve patient care. Educational
resentations on the importance of Tdap immunization could be
iven at prenatal classes. Additional immunization clinic times
n pediatric and family practice ofﬁces may  be considered in the
uture.
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